Swiss-based medical technology company MedAlliance has been acquired by Cordis in a deal that could be worth up to $1.1 billion. The deal consists of a 2022 investment of $35 million and a 2023 upfront closing payment of $200 million, together with regulatory achievement milestones of up to $125 million and commercial milestones of up to $775 million through 2029. Cordis is a developer and manufacturer of interventional cardiovascular and endovascular technologies. MedAlliance’s sirolimus drug-eluting balloon (DEB) program, SELUTION SLR (Sustained Limus Release), has provided a flagship product family which complements Cordis’ existing product portfolio.
Medical Device Supply Chain Council